Traders Market Weekly: September 12 to 18 2021


Gapping up
In reaction to earnings/guidance:

BBW +1.8% (reaffirms guidance in presentation)

Other news:

AZRX +11.2% (CEO issues letter to shareholders regarding recent acquisition of First Wave Bio and creation of First Wave BioPharma)
AXSM +8% (FDA accepts NDA for migraine treatment AXS-07; PDUFA date set for April 30, 2022)
KERN +7.9% (to acquire 365 Cannabis in a $17 mln deal)
ZLAB +7.7% (receives Breakthrough Therapy Designation for Bemarituzumab in China)
PNT +6.1% (POINT Biopharma and Convergent Therapeutics announce collaboration to evaluate CONV 01-a (Rosopatamab-225Ac) in combination with PNT2002)
NRXP +6% (IQV to collaborate with NRXP on potential medical support for novel COVID-19 treatment)
AVNT +4.6% (expects double-digit revenue in its composite solutions)
SPIR +4.1% (to acquire exactEarth (EXRTF) for approx. $161.2 mln in cash and stock; to be accretive to revs, adj. EBITDA)
ANGI +3.6% (report monthly metrics for August)
ARAY +3.5% (reports CyberKnife Robotic Radiotherapy Platform is superior to conventional linear accelerators)
QTRX +3.3% (FDA expands EUA label for its Simoa SARS-CoV-2 N Protein Antigen Test)
GLDD +3% (announces receipt of several major dredging awards totaling $261.3 mln)
VCTR +2.3% (reports August AUM)
INCY +1.1% (Ruxolitinib Cream data accepted for presentation at EADV)
NVCR +1.1% (has entered into a clinical trial collaboration agreement with Roche (RHHBY))
MNR +1% (reinitiates exploration of strategic alternatives)
RWT +1% (increases dividend)
SENS +1% (announces collaboration with the University Hospitals)

Analyst comments:

JNCE +4.6% (upgraded to Outperform from Mkt Perform at Raymond James)
DXC +1.9% (upgraded to Buy from Neutral at BofA Securities)
LESL +1.3% (upgraded to Buy from Hold at Berenberg)
KLAC +0.9% (upgraded to Positive from Neutral at Susquehanna)